Enzo Biochem (NYSE:ENZ) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZ) in a research note published on Tuesday. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Stock Performance

NYSE:ENZ opened at $0.70 on Tuesday. Enzo Biochem has a fifty-two week low of $0.68 and a fifty-two week high of $1.50. The company has a fifty day moving average of $1.09 and a two-hundred day moving average of $1.11.

Enzo Biochem (NYSE:ENZ) last released its earnings results on Monday, December 16th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter. Enzo Biochem had a negative return on equity of 11.84% and a negative net margin of 81.73%.

Enzo Biochem Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 15th were issued a $0.10 dividend. This represents a $0.40 dividend on an annualized basis and a dividend yield of 57.14%. The ex-dividend date was Friday, November 15th.

Institutional Investors Weigh In On Enzo Biochem

Hedge funds have recently modified their holdings of the company. BBR Partners LLC purchased a new stake in shares of Enzo Biochem in the third quarter valued at about $112,000. Renaissance Technologies LLC lifted its position in Enzo Biochem by 2.6% in the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after buying an additional 64,417 shares during the last quarter. XTX Topco Ltd lifted its position in Enzo Biochem by 94.5% in the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after buying an additional 13,735 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in Enzo Biochem by 3.3% in the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock valued at $413,000 after buying an additional 11,742 shares during the last quarter. Hedge funds and other institutional investors own 36.90% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.